Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 9/2007

01-09-2007 | Original Article

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients

Authors: J. M. Li, L. Wang, Y. Shen, Z. G. Xia, Y. Chen, Q. S. Chen, Y. Chen, X. Y. Zeng, J. H. You, Y. Qian, Z. X. Shen

Published in: Annals of Hematology | Issue 9/2007

Login to get access

Abstract

The objective of this study is to evaluate the long-term efficacy and safety of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in Chinese patients with newly diagnosed diffuse large B cell lymphoma (DLBCL). The study comprised a retrospective analysis of patients treated at a single center. Patients received four to six infusions of rituximab (375 mg/m2 per dose) on day 1 of each cycle of CHOP chemotherapy. CHOP was initiated on day 3 of each cycle; cycles were repeated at 21-day intervals. A total of 82 patients with a median age of 45 years (range 18–76 years) was included. The overall response (OR) and complete response (CR) rates were 90.2 and 70.7%, respectively. The estimated 5-year progression-free survival (PFS) and overall survival (OS) rates were 56.4 ± 8.3% and 74.1 ± 7.4%, respectively. Patients with International Prognostic Index (IPI) scores ≤2 had significantly higher OR, CR, PFS, and OS rates (p = 0.01, p = 0.02, p = 0.01, p < 0.001, respectively) compared with patients with IPI scores >2. The hematologic toxicity was mild. Five patients with a history of chronic hepatitis B experienced a reactivation of viral hepatitis. The rituximab–CHOP combination was effective and well tolerated in Chinese patients with newly diagnosed DLBCL.
Literature
1.
Akhtar S, Maghfoor I (2002) Rituximab plus CHOP for diffuse large-B-cell lymphoma. N Engl J Med 346:1830–1831PubMedCrossRef
2.
Cancer Therapy Evaluation Program (1998) Common toxicity criteria, version 2.0. National Cancer Institute, Bethesda
3.
Chen Y, Du H, Hu WW et al (2004) Clinicopathologic analysis and classification of 365 cases of non-Hodgkin’s lymphomas according to the new WHO criteria. Chin J Diagn Pathol 11:304–307
4.
5.
Cheson BD, Horning SJ, Coiffier B et al (1999) for the NCI-sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 17:1244PubMed
6.
Chuang SS, Lin CN, Li CY (2000) Malignant lymphoma in southern Taiwan according to the revised European–American classification of lymphoid neoplasms. Cancer 89:1586–1592PubMedCrossRef
7.
Coiffier B (1994) What treatment for elderly patients with aggressive lymphoma? Ann Oncol 5:873–875PubMed
8.
Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242PubMedCrossRef
9.
Colombat P, Salles G, Brousse N et al (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97:101–106PubMedCrossRef
10.
Czuczman MS, Fallon A, Mohr A et al (2002) Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 29(1 Suppl 2):36–40PubMedCrossRef
11.
Dai MS, Chao TY, Kao WY et al (2004) Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 83:769–774PubMedCrossRef
12.
Dang NH, Hagemeister FB, Pro B et al (2004) Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol 22:4095–4102PubMedCrossRef
13.
Davis TA, White CA, Grillo-López AJ et al (1999) Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab. J Clin Oncol 17:1851PubMed
14.
Dixon DO, Neilan B, Jones SE et al (1986) Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 4:295–305PubMed
15.
Fisher RI, Gaynor ER, Dahlberg S et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006PubMedCrossRef
16.
17.
Guan ZZ, Yu LH, He YJ et al (1989) CHOP treatment of NHL, a report of 103 cases. Chin J Cancer 8:98–100
18.
Habermann T, Weller E, Morrison V et al (2003) Phase III trial of rituximab-CHOP (R-CHOP) vs CHOP with a second randomisation to maintenance rituximab (MR) or observation in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL). Blood 102:8a
19.
Haioun C, Lepage E, Gisselbrecht C et al (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol—a Groupe d’Etude des Lymphomes de l’Adulte study. J Clin Oncol 18:3025–3030PubMed
20.
Harris NL, Jaffe ES, Stein H et al (1994) A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361–1392PubMed
21.
He S, Zhang JB, Zhang JG et al (2003) The WHO(1997) classification of 370 cases of malignant lymphomas. Chin J Hematol 24:519–522
22.
Hochster HS, Weller E, Ryan T et al (2004) Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Proc Am Soc Clin Oncol 23:556
23.
Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon
24.
Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef
25.
Leaw SJ, Yen CJ, Huang WT et al (2004) Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 83:270–275PubMedCrossRef
26.
Li JM, Shen Y, Chen FY et al (2003) A multi-center clinical study of anti-CD20 monoclonal antibody in combination with CHOP regimen for treatment of diffuse large B cell lymphoma. Chin J Cancer Biother 10:157–160
27.
Lin TY, Zhang HY, Huang Y et al (2005) Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China—a multi-center randomized trial. Ai Zheng 24(12):1421–1426PubMed
28.
Lorand-Metze I, Pereira FG, Costa FP et al (2004) Proliferation in non-Hodgkin’s lymphomas and its prognostic value related to staging parameters. Cell Oncol 26:63–71PubMed
29.
McLaughlin P, Grillo-Lopez AJ, Link BK et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833PubMed
30.
Morrison VA, Weller EA, Habermann TM (2004) Patterns of growth factor (GF) usage and febrile neutropenia (FN) among older patients (pts) with diffuse large B-cell lymphoma (DLBCL) treated with CHOP or R-CHOP: an intergroup experience (CALGB 9793, ECOG-SWOG 4494). Blood 104:3309
31.
Pfreundschuh M, Kloess M, Schmits R et al (2005) Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 106:9a
32.
Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379–391PubMedCrossRef
33.
Rossini F, Terruzzi E, Perego D et al (2004) Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone. Cancer 100:350–355PubMedCrossRef
34.
Sonneveld P, de Ridder M, van der Lelie H et al (1995) Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin’s lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 13:2530–2539PubMed
35.
Tobinai K, Igarashi T, Itoh K et al (2004) Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15:821–830PubMedCrossRef
36.
Vose JM, Link BK, Grossbard ML et al (2001) Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol 19:389–397PubMed
37.
Wu HJ, Zhang QY, Chen DF et al (2005) Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma. Ai Zheng 24:1498–1502PubMed
38.
Yin HF, Li T, Li JX (2003) Retrospective analysis of 304 cases of malignant lymphomas in pathology: study and practice of the WHO classification of lymphoid neoplasms. Zhonghua Yi Xue Za Zhi 83(18):1556–1560PubMed
39.
Zhang HY, Lin TY, Jiang WQ et al (2004) Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell Non-Hodgkin’s lymphoma. Chin J Cancer 23:1681–1686
40.
Zhang YN, Zhou XG, Zhang SH et al (2005) Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 World Health Organization classification of lymphoid neoplasms. Zhonghua Bing Li Xue Za Zhi 34:193–197PubMed
Metadata
Title
Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients
Authors
J. M. Li
L. Wang
Y. Shen
Z. G. Xia
Y. Chen
Q. S. Chen
Y. Chen
X. Y. Zeng
J. H. You
Y. Qian
Z. X. Shen
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 9/2007
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-007-0320-8

Other articles of this Issue 9/2007

Annals of Hematology 9/2007 Go to the issue

Original Article

A novel mutation of −73(A→T) in the CCAAT box of the β-globin gene identified in a patient with the mild β-thalassemia intermedia

Letter to the Editor

Management of inherited dysfibrinogenemia during pregnancy: a description of four consecutive cases

Letter to the Editor

Primary cardiac lymphoma presenting with right heart mass and bradycardia

Original Article

Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies

Letter to the Editor

Extramedullary hemopoiesis with littoral cell angioma involving main and accessory spleens

Original Article

Physician perceptions and preferences in the treatment of acquired immunodeficiency syndrome (AIDS)-related lymphoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits